.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA03_Pegaptanib.Pegaptanib .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA03_Pegaptanib.Pegaptanib| name: | Pegaptanib |
| ATC code: | S01LA03 | route: | intravitreal |
| n-compartments | 1 |
Pegaptanib is an anti-VEGF (vascular endothelial growth factor) aptamer administered by intravitreal injection for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was formerly approved for this indication, but newer therapies have largely replaced its use.
Pharmacokinetics in adult patients with neovascular AMD after intravitreal injection.
Basile, AS, et al., & Nickens, DJ (2015). Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema. Clinical ophthalmology (Auckland, N.Z.) 9 323–335. DOI:10.2147/OPTH.S74050 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25733800